Cargando…
Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study
We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log(10) with XF-73 compared to 0.4 log(10)...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cambridge University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369221/ https://www.ncbi.nlm.nih.gov/pubmed/36951472 http://dx.doi.org/10.1017/ice.2023.17 |
| _version_ | 1785077710543912960 |
|---|---|
| author | Mangino, Julie E. Firstenberg, Michael S. Milewski, Rita K.C. Rhys-Williams, William Lees, James P. Dane, Aaron Love, William G. Gonzalez Moreno, Jesus |
| author_facet | Mangino, Julie E. Firstenberg, Michael S. Milewski, Rita K.C. Rhys-Williams, William Lees, James P. Dane, Aaron Love, William G. Gonzalez Moreno, Jesus |
| author_sort | Mangino, Julie E. |
| collection | PubMed |
| description | We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log(10) with XF-73 compared to 0.4 log(10) CFU/mL for those who received placebo (95% CI, −2.7 to −1.5; P < .0001). |
| format | Online Article Text |
| id | pubmed-10369221 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Cambridge University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103692212023-07-27 Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study Mangino, Julie E. Firstenberg, Michael S. Milewski, Rita K.C. Rhys-Williams, William Lees, James P. Dane, Aaron Love, William G. Gonzalez Moreno, Jesus Infect Control Hosp Epidemiol Concise Communication We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log(10) with XF-73 compared to 0.4 log(10) CFU/mL for those who received placebo (95% CI, −2.7 to −1.5; P < .0001). Cambridge University Press 2023-07 2023-03-23 /pmc/articles/PMC10369221/ /pubmed/36951472 http://dx.doi.org/10.1017/ice.2023.17 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
| spellingShingle | Concise Communication Mangino, Julie E. Firstenberg, Michael S. Milewski, Rita K.C. Rhys-Williams, William Lees, James P. Dane, Aaron Love, William G. Gonzalez Moreno, Jesus Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title | Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title_full | Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title_fullStr | Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title_full_unstemmed | Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title_short | Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study |
| title_sort | exeporfinium chloride (xf-73) nasal gel dosed over 24 hours prior to surgery significantly reduced staphylococcus aureus nasal carriage in cardiac surgery patients: safety and efficacy results from a randomized placebo-controlled phase 2 study |
| topic | Concise Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369221/ https://www.ncbi.nlm.nih.gov/pubmed/36951472 http://dx.doi.org/10.1017/ice.2023.17 |
| work_keys_str_mv | AT manginojuliee exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT firstenbergmichaels exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT milewskiritakc exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT rhyswilliamswilliam exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT leesjamesp exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT daneaaron exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT lovewilliamg exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study AT gonzalezmorenojesus exeporfiniumchloridexf73nasalgeldosedover24hourspriortosurgerysignificantlyreducedstaphylococcusaureusnasalcarriageincardiacsurgerypatientssafetyandefficacyresultsfromarandomizedplacebocontrolledphase2study |